This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SQ109
Description: SQ109 is an orally active diamine antibiotic targeted for the treatment of tuberculosis (TB). The compound inhibits cell wall synthesis in a select group of microorganisms via a mechanism of action distinct from other antibiotics used in TB therapy. The drug has shown in vitro activity against both drug susceptible and drug resistant TB bacteria, including XDR-TB. In in vivo and in vitro studies, SQ109 has enhanced the activity of the anti-tubercular drugs Isoniazid and Rifampin.
Deal Structure: SQ109 was co-discovered by scientists at Sequella and the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), under a Cooperative Research and Development Agreement.
In April 2011, Sequella and the Maxwell Biotech Venture Fund entered an agreement to complete the clinical development and commercialize SQ109 for treatment of tuberculosis (TB) in the Russian Federation and neighboring Commonwealth of Independent States (CIS) countries, including Armenia, Azerbaijan, Belorussia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Ukraine.
Additional information available to subscribers only: